AstraZeneca sues Taro in blood-thinning drug patent dispute

24-02-2022

AstraZeneca sues Taro in blood-thinning drug patent dispute

Mats Wiklund / Shutterstock.com

AstraZeneca has sued Taro Pharmaceuticals in two US federal courts alleging that Taro’s planned generic blood-thinning treatment infringes a patent for its Brilinta (ticagrelor) medication.


AstraZeneca, Taro, dispute, patent

LSIPR